Long-Term Evaluation of Antiphospholipid Antibodies in Patients with COVID-19

Ghilardi, Guido; Kessler, Chiara; Colucci, Giuseppe; Elzi, Luigia; Bernasconi, Enos; Monotti, Rita; Llamas, Michael; Ferrari, Paolo; Keller, Franco; Brenni, Mirko; Petrilli, Maria Pia; Rossi, Davide; Stüssi, Georg; Gerber, Bernhard

doi:10.2139/ssrn.3781640

Search citation statements

Order By: Relevance

Paper Sections

Select...

Antiphospholipid Antibodies In Covid-191

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Also, of interest is the persistence of APLAs following recovery, as according to revised antiphospholipid syndrome (APS) diagnostic guidelines from a conference in Sapporo, Japan only the persistent presence of APLAs can be considered to be a serologic marker of APS. 253 Ghilardi et al 254 performed a prospective study including COVID-19 patients admitted to the intensive care unit due to disease severity. At admission, the prevalence of LA, aCL, and β2-GPI was 36.5%, 12.5%, and 15.6% respectively, which is comparable to previously described conclusions.…”

Section: Antiphospholipid Antibodies In Covid-19mentioning

confidence: 99%